This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New Strong Sell Stocks for July 15th
by Zacks Equity Research
DDD, AVNS and BABA have been added to the Zacks Rank #5 (Strong Sell) List on July 15, 2025.
Avanos Medical (AVNS) International Revenue in Focus: Trends and Expectations
by Zacks Equity Research
Explore Avanos Medical's (AVNS) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
New Strong Sell Stocks for May 9th
by Zacks Equity Research
AVNS, BCC and AMPY have been added to the Zacks Rank #5 (Strong Sell) List on May 9, 2025.
AVNS Stock Gains Post Q1 Earnings & Revenue Beat, Gross Margin Down
by Zacks Equity Research
Strength in Avanos' SNS segment drives its first-quarter 2025 performance despite global macroeconomic challenges.
Avanos Medical (AVNS) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 36.84% and 2.04%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
AVNS Stock Gains Following Direct Sales Deal for MIC-KEY in the UK
by Zacks Equity Research
Avanos takes direct control of MIC-KEY sales in the UK, enhancing market presence, customer engagement and service efficiency, starting July 2025.
Avanos Medical (AVNS) Down 5.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Avanos Medical (AVNS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for March 24th
by Zacks Equity Research
AVNS, AIRS and AMPH have been added to the Zacks Rank #5 (Strong Sell) List on March 24, 2025.
New Strong Sell Stocks for March 18th
by Zacks Equity Research
AVNS, CARS and CABO have been added to the Zacks Rank #5 (Strong Sell) List on March 18, 2025.
Do Options Traders Know Something About Avanos (AVNS) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Avanos (AVNS) stock based on the movements in the options market lately.
New Strong Sell Stocks for March 3rd
by Zacks Equity Research
AVNS, CSX and STZ have been added to the Zacks Rank #5 (Strong Sell) List on March 3, 2025.
AVNS Stock Gains Post Q4 Earnings & Revenue Beat, Margins Contract
by Zacks Equity Research
Strength in Avanos' Digestive Health segment drives its fourth-quarter 2024 performance despite global macroeconomic challenges.
Avanos Medical (AVNS) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 7.50% and 1.06%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Avanos Medical (AVNS) Soars 7.2%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Avanos Medical (AVNS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Reasons to Hold Avanos Medical Stock in Your Portfolio Now
by Zacks Equity Research
AVNS' strong product line and focus on R&D raise optimism about the stock.
New Strong Sell Stocks for December 11th
by Zacks Equity Research
AVNS, BATRK and ELV have been added to the Zacks Rank #5 (Strong Sell) List on December 11, 2024.
CAH Stocks Gains on Q1 Earnings & Sales Beat and Raised '25 EPS View
by Zacks Equity Research
Cardinal Health's first-quarter fiscal 2025 results benefit from solid Pharmaceutical and Specialty Solutions growth. However, OptumRx contract expiry hurts sales.
Are Investors Undervaluing Avanos Medical (AVNS) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Avanos Q3 Earnings Meet Estimates, Sales Miss, Gross Margin Contracts
by Zacks Equity Research
Strength in AVNS' Digestive Health segment drives its third-quarter performance
CONMED Beats on Q3 Earnings, Misses on Sales, Lowers '24 Sales View
by Zacks Equity Research
CNMD's Q3 earnings beat estimates on the back of higher revenues and lower costs and expenses.
GE HealthCare Q3 Earnings Beat Estimates, Sales Meet, Net Margin Up
by Zacks Equity Research
GEHC's third-quarter results witness declining segmental revenues in imaging and ultrasound, offset by strong Pharmaceutical Diagnostics performance. The bottom line improves on better pricing.
Avanos Medical (AVNS) Q3 Earnings Meet Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 0% and 2.65%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Inari Medical Q3 Earnings Miss Estimates, Revenues Increase Y/Y
by Zacks Equity Research
NARI's third-quarter results witness an increase in revenues with dismal bottom-line performance. Gross margins contract while the company continues to incur operating losses.
TransMedics Stock Falls as Q3 Earnings & Sales Miss Estimates
by Zacks Equity Research
TMDX's third-quarter revenues increase with the utilization of the OCS across all three organs and additional revenues generated by its logistics services. Gross margin contracts.
West Pharmaceutical Stock Gains on Q3 Earnings Beat & Raised Guidance
by Zacks Equity Research
WST's third-quarter results reflect a recovery in the Proprietary Products segment following elevated customer destocking, hurting sales in the second quarter.